Are functional heartburn and functional dyspepsia one disorder?

Nature Reviews Gastroenterology and Hepatology

Volumn 7, Issue 2, 2010, Pages 71-72

  Hershcovici, Tiberiu ^a   Fass, Ronnie ^a  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

BARRETT ESOPHAGUS; BLOATING; CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG TREATMENT FAILURE; DYSPEPSIA; DYSPHAGIA; EPIGASTRIC PAIN; ESOPHAGUS DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HEARTBURN; HUMAN; MONITORING; NAUSEA AND VOMITING; PH; PREVALENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SCLERODERMA; SHORT SURVEY; SYMPTOM; CLASSIFICATION; NOTE;

DYSPEPSIA; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS;

EID: 76949108198     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.233     Document Type: Short Survey

References (12)

1. Drossman, D. A. et al. U.s. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig. Dis. Sci. 38, 1569-1580 (1993).
2. Fass, R. & Tougas, G. Functional heartburn: the stimulus, the pain, and the brain. Gut 51, 885-892 (2002).
3. Savarino, E. et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 58, 1185-1191 (2009).
4. Savarino, E. et al. The role of nonacid reflux in neRD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am. J. Gastroenterol. 103, 2685-2693 (2008).
5. Savarino, E. et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am. J. Respir. Crit. Care Med. 179, 408-413 (2009).
6. Fass, R. & sifrim, D. Management of heartburn not responding to proton pump inhibitors. Gut 58, 295-309 (2009).
7. Fass, R. Erosive esophagitis and nonerosive reflux disease (neRD): comparison of epidemiologic, physiologic and therapeutic characteristics. J. Clin. Gastroenterol. 41, 131-137 (2007).
8. Drossman, D. (ed.) Rome III: The Functional Gastrointestinal Disorders, 3rd edn (Degnon Associates, inc., McLean, vA, 2006).
9. Bardhan, K. D. Look-but also listen! ReQuest: a new dimension-oriented GeRD symptom scale. Drugs Today (Barc.) 40 (suppl. A), 15-19 (2004).
10. Carlsson, R. et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. international GORD study Group. Eur. J. Gastroenterol. Hepatol. 10, 119-124 (1998).
11. Kahrilas, P. J. et al. efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease. Dig. Dis. Sci. 50, 2009-2018 (2005).
12. Dean, B. B., Gano, A. D. Jr, Knight, K., Ofman, J. J. & Fass, R. effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin. Gastroenterol. Hepatol. 2, 656-664 (2004).